Dose Escalation of Blinatumomab Is a Better Option for MRD-Positive CR Patients, Results from a Single-Center Real World Study of Blinatumomab for B-Cell Acute Lymphoblastic Leukemia in China
BLOOD(2023)
Abstract
Background:Blinatumomab(Blincyto) is a CD3-CD19 bispecific T-cell engager for treating B-cell acute lymphoblastic leukemia(B-ALL). Blincyto has been available in China since Aug 2021. Standard treatment duration of Blincyto is 28 days(d) per cycle. Due to economic reasons, part of the Chinese patients(pts) received 14d of infusion per cycle. Whether the 14-d regimen impact outcomes remains uncertain. To investigate the efficacy of 14-d regimen, we retrospectively analyzed the data of pts treated with Blincyto in our center.
MoreTranslated text
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined